Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Presentation Materials on the Issuance of Series 12 Stock Acquisition Rights with an Exercise Price Adjustment Clause and Series 3 Unsecured Corporate Bonds through a Private Placement

The materials explain the purpose, use of proceeds, terms and financing scheme for raising funds through the 12th Stock Acquisition Rights and the 3rd Unsecured Corporate Bonds. They do not provide details of any existing disclosure subject to correction or figures before and after the correction.

Worth reading
—
Scored from 0 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure
The number of days elapsed cannot be calculated because the original disclosure date is unknown.
This correction2026-07-22
What was corrected and how
ItemDetails
Items this document does not state (6)
Disclosure subject to correctionOriginal disclosure dateLocation of correctionDetails of correctionReason for correctionImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No reason for the correction is provided.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Presentation Materials on the Issuance of Series 12 Stock Acquisition Rights with an Exercise Price Adjustment Clause and Series 3 Unsecured Corporate Bonds through a Private Placement | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori